May 13, 2014
11:00 a.m. to 12:00 pm EDT

Sponsored by

Webinar Description:

Participants will be provided a basic overview of the premise of metabolomics and a brief explanation as to why it has become such a key science in systems biology. We will then extensively elaborate on how, if metabolomics is to provide the same degree of in depth coverage of the entirety of metabolism (i.e. the metabolome) that current DNA sequencers provide with high fidelity and cost-effectiveness, that it is critical that is be composed of certain technological and informatics features. Finally, we will describe recent examples of how, with deployment of a metabolomic technology adopting these key elements, important breakthroughs in diagnostics and life science research have occurred.

Learning Objectives:

  • Understand the essential features of metabolomics and why it is key to life science research
  • Understand how metabolomic technologies are diverse in approach but some are scalable and on par with today’s most modern DNA sequencers
  • Understand why technology approaches are critical for meaningful metabolomic results, and hence, achievement of overall research goals

Many approaches but the current gold standard for serving these requirements is composed of 5 critical features that a metabolomic technology must harbor in order for it to achieve a similar purpose as mature omic technologies (e.g. DNA sequencers) in terms of depth of coverage and data quality. These minimally include:

1. Must be based on an authenticated chemical library
2. From this library, should make IDs through a combination of accurate emass, retention index and fragmentation
3. Must have procedures for eliminated noise from the data
4. Must have a mechanism to identify novel metabolites
5. Must have robust QC process from sample preparation through statistical analysis
6. Must provide a mechanism to abstract information/interpret the data

Elaborating on the details around each of these points is beyond the scope of this series but should serve as a primer for beginning the discussion with a partner for metabolomic work.


Brante SampeyBrante Sampey, Ph.D.

Sr. Study Director, US Pharma/Biotech

Metabolon, Inc.

Brante is a Sr. Study Director within the US Pharma/Biotech division of Metabolon, specializing in obesity, metabolic disease and cancer metabolism. Dr. Sampey’s projects encompass target discovery, drug mechanism and biomarker identification. He has been an accomplished contributor in driving several application areas forward for Metabolon’s metabolic profiling technology. Chief among these are the application of Metabolomics in biomarker discovery and the strategic development of diagnostic tools. Metabolon has completed over 3000 studies, and the scientific team has published over 300 peer-reviewed articles with many of Metabolon’s clients.

Cost: No cost!